Development of a decision aid with cost information for heart failure medication in Singapore

Qianyu Shen , Dennis Chin Wee Chua , Po Fun Chan , Hwee Lin Wee
{"title":"Development of a decision aid with cost information for heart failure medication in Singapore","authors":"Qianyu Shen ,&nbsp;Dennis Chin Wee Chua ,&nbsp;Po Fun Chan ,&nbsp;Hwee Lin Wee","doi":"10.1016/j.pecinn.2024.100342","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This study presents the development process of a heart failure (HF) medication decision aid (DA) specific to Singapore context, with the objective of promoting cost conversations.</p></div><div><h3>Methods</h3><p>Phase 1 was to create a DA prototype, where two HF clinicians were consulted on their input and needs. Phase 2 was pilot testing where the prototype was tested on HF patients and revised based on their feedback.</p></div><div><h3>Results</h3><p>The DA is a one-page poster that compares only two classes of HF medications. It encompasses seven attributes for comparison, including route of administration, treatment duration, frequency of use, hospitalization rate, survival rate, low blood pressure probability with personalized subsidized cost being the key attribute. A total of 48 patients participated in the pilot testing with only 2 patients (4.2 %) finding the DA difficult to understand. Almost all patients agreed that the DA provided greater clarity in the medication options.</p></div><div><h3>Conclusion</h3><p>By integrating the needs of both clinicians and patients and conducting user testing, we developed a novel HF medication DA. Patients found the tool easy to understand and acceptable.</p></div><div><h3>Innovation</h3><p>This innovative DA aims to improve cost conversations by providing tailored, concise, and locally relevant information for efficient use.</p></div>","PeriodicalId":74407,"journal":{"name":"PEC innovation","volume":"5 ","pages":"Article 100342"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772628224000906/pdfft?md5=a9b719afd88e89238b9a35ebc233cb38&pid=1-s2.0-S2772628224000906-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PEC innovation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772628224000906","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

This study presents the development process of a heart failure (HF) medication decision aid (DA) specific to Singapore context, with the objective of promoting cost conversations.

Methods

Phase 1 was to create a DA prototype, where two HF clinicians were consulted on their input and needs. Phase 2 was pilot testing where the prototype was tested on HF patients and revised based on their feedback.

Results

The DA is a one-page poster that compares only two classes of HF medications. It encompasses seven attributes for comparison, including route of administration, treatment duration, frequency of use, hospitalization rate, survival rate, low blood pressure probability with personalized subsidized cost being the key attribute. A total of 48 patients participated in the pilot testing with only 2 patients (4.2 %) finding the DA difficult to understand. Almost all patients agreed that the DA provided greater clarity in the medication options.

Conclusion

By integrating the needs of both clinicians and patients and conducting user testing, we developed a novel HF medication DA. Patients found the tool easy to understand and acceptable.

Innovation

This innovative DA aims to improve cost conversations by providing tailored, concise, and locally relevant information for efficient use.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在新加坡开发包含心力衰竭用药成本信息的决策辅助工具
本研究介绍了针对新加坡国情的心力衰竭(HF)用药决策辅助工具(DA)的开发过程,目的是促进成本对话。方法第一阶段是创建一个DA原型,咨询两位HF临床医生的意见和需求。第 2 阶段是试点测试,在高血压患者身上测试原型,并根据他们的反馈意见进行修改。结果DA 是一张单页海报,仅对两类高血压药物进行比较。它包含七个比较属性,包括给药途径、疗程、使用频率、住院率、存活率、低血压概率,其中个性化补贴费用是关键属性。共有 48 名患者参与了试点测试,仅有 2 名患者(4.2%)认为 DA 难以理解。通过综合考虑临床医生和患者的需求并进行用户测试,我们开发出了一种新型的高血压药物DA。患者认为该工具易于理解和接受。创新这一创新型 DA 旨在通过提供量身定制、简明扼要且与当地相关的信息,提高使用效率,从而改善成本对话。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
PEC innovation
PEC innovation Medicine and Dentistry (General)
CiteScore
0.80
自引率
0.00%
发文量
0
审稿时长
147 days
期刊最新文献
Measuring professionals' attitudes toward persistent somatic symptoms: Development, validation, and reliability of the professionals' Attitude to Persistent Somatic Symptoms Questionnaire (PAPSS) Tech + touch: A pilot study to facilitate access to health information technology for Spanish-speaking parents Single-encounter elicitation framework for diagnostic excellence patient-reported measures: SEE-Dx-PRM The effectiveness of integrating making every contact count into an undergraduate medical curriculum How often are patients recording their healthcare consultations in Australia and why? An online survey
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1